StockData
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc. (AVIR) stock

AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$3.96−0.16 (-3.88%)

Close on Nov 17, 2026Market cap $317.61MP/E –Yield –

Atea Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Atea Pharmaceuticals's cash was $219.47M at Jun 30, 2026. For fiscal 2025 it was $301.83M, down 33.6% from the year before. The highest annual figure on record is $850.12M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$301.83M-33.6%
FY2024Dec 31, 2024$454.72M-21.3%
FY2023Dec 31, 2023$578.10M-10.6%
FY2022Dec 31, 2022$646.71M-15.4%
FY2021Dec 31, 2021$764.68M-10.1%
FY2020Dec 31, 2020$850.12M+3805.4%
FY2019Dec 31, 2019$21.77M-37.1%
FY2018Dec 31, 2018$34.60M+130.1%
FY2017Dec 31, 2017$15.04M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$219.47M-42.2%
Q1 FY2026Mar 31, 2026$256.01M-39.8%
Q4 FY2025Dec 31, 2025$301.83M-33.6%
Q3 FY2025Sep 30, 2025$329.31M-31.8%
Q2 FY2025Jun 30, 2025$379.71M-24.4%
Q1 FY2025Mar 31, 2025$425.44M-21.4%
Q4 FY2024Dec 31, 2024$454.72M-21.3%
Q3 FY2024Sep 30, 2024$482.80M-18.9%
Q2 FY2024Jun 30, 2024$502.20M-17.4%
Q1 FY2024Mar 31, 2024$541.50M-12.7%
Q4 FY2023Dec 31, 2023$578.10M-10.6%
Q3 FY2023Sep 30, 2023$595.10M-10.5%
Q2 FY2023Jun 30, 2023$608.10M-11.2%
Q1 FY2023Mar 31, 2023$620.49M-12.1%
Q4 FY2022Dec 31, 2022$646.71M-15.4%
Q3 FY2022Sep 30, 2022$664.98M-20.8%
Q2 FY2022Jun 30, 2022$684.48M-16.2%
Q1 FY2022Mar 31, 2022$705.55M-15.4%
Q4 FY2021Dec 31, 2021$764.68M-10.1%
Q3 FY2021Sep 30, 2021$839.66M+696.8%
Q2 FY2021Jun 30, 2021$816.46M+605.1%
Q1 FY2021Mar 31, 2021$833.75M+4762.4%
Q4 FY2020Dec 31, 2020$850.12M+3805.4%
Q3 FY2020Sep 30, 2020$105.38M+311.6%
Q2 FY2020Jun 30, 2020$115.79M+234.7%
Q1 FY2020Mar 31, 2020$17.15M+14.0%
Q4 FY2019Dec 31, 2019$21.77M–
Q3 FY2019Sep 30, 2019$25.60M–
Q4 FY2018Dec 31, 2018$34.60M–
Q4 FY2017Dec 31, 2017$15.04M–

More Atea Pharmaceuticals figures

See a number that looks wrong?